Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
PROGRAM Molecular UTI Conference Urinary Tract Infection; molecular advances and novel therapies Malmö, August 25-‐‑27th, 2014 Conference venue: The Jubilee auditorium Jan Waldenströms gata 1-‐‑5, Malmö MONDAY August 25th 08.50 Opening remarks 09.00 KEY NOTE LECTURE Bruce Beutler, Regental Professor, Director, Center for Genetics of Host Defense, University of Texas, Southwestern Medical Center, Dallas, Texas, USA Coffee 10.00 SESSION 1: HOST SUSCEPTIBILITY TO INFECTION Chair: Bruce Beutler Antimicrobial peptides and proteins in defense of the urinary tract Michael Zasloff, Medstar Georgetown Transplant Institute, Georgetown University School of Medicine, Washington DC, USA Using bacteria to understand human innate immune variation Sam Miller, Department of Microbiology, University of Washington, Seattle, Washington, USA Innate Immunity and Genetic Determinants of UTI susceptibility Catharina Svanborg, Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden Genetic Variation in Vesicoureteral Reflux and its Sequelae David Hains, Health Science Center, Department of Pediatrics, Division of Pediatric Nephrology, University of Tennessee, Memphis, Tennessee, USA Genetic control of acute cystitis; IL-1β and inflammasome dysregulation Gustav Rydström, Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden 13.0014.00 Lunch 14.00 SESSION 2: HOST RESPONSE MODULATION BY BACTERIA INFECTING THE URINARY TRACT Chairs: Soman Abraham, Ann Stapleton Unique immune responses of the bladder that predispose to bacterial persistence Soman Abraham, Center for Microbial Pathogenesis, Duke University Medical Center, Durham, North Carolina, USA Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/ interleukin-1 receptor domain–containing proteins Thomas Miethke, Institute of Medical Microbiology and Hygiene, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany Bacterial control of host gene expression through RNA polymerase II Ines Ambite, Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden 16.00 Coffee The fractalkine receptor and its role in glomerulonephritis and pyelonephritis. Christian Kurts, Institute of Experimental Immunology, University of Bonn, Bonn, Germany Innate Immune Suppression by UPEC David Hunstad, Department of Pediatrics & Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, Missouri, USA Macrophage depletion improves adaptive immunity to uropathogen infection Molly Ingersoll, Institut Pasteur, INSERM U818, Paris, France TUESDAY August 26th 08.30 SESSION 3: PATHOGENESIS Chairs: Diana Karpman, John Connolly Redefining ExPEC Virulence by Measuring Gene Expression during Human Infection Harry Mobley, Department of Microbiology & Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA Targeted migration of leukocytes: Role of sentinel and helper cells Daniel Engel, Institute of Experimental Immunology, University Clinic of Bonn Survival Strategies of Uropathogenic E. coli Matthew Mulvey, Department of Pathology, Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake City, Utah, USA Lifting the Mask: Second Generation Small Molecule Inhibitors of Uropathogenic E. coli Group 2 Capsule Biogenesis Patrick C. Seed, Division of Infectious Diseases, Department of Pediatrics & Department of Molecular Genetics and Microbiology, Duke University Hospital, Duke University, Durham, North Carolina, USA 11.00 Coffee Bacterial pain phenotypes in the urinary tract David Klumpp, Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA Midstream urine culture in the diagnosis of acute uncomplicated cystitis Thomas M. Hooton, Department of Medicine, Division of Infectious Diseases, University of Miami, Miami, Florida, USA Type 1 pili mediate adhesion-based signaling in uropathogenic E. coli Eric Klein, Center for computational and integrative biology, Rutgers University, Camden, New Jersey, USA 13.0014.00 Lunch 14. 00 SESSION 4: ASYMPTOMATIC BACTERIAL CARRIAGE – GENOMES AND HOSTS Chairs: David Hains, Gabriela Godaly The paradigm shift to non-treatment in ABU Lindsay Nicolle, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba, Canada Deliberate establishment of bacteriuria – the therapeutic and research model Björn Wullt, Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, Lund, Sweden Virulence gene attenuation and genome evolution in human hosts Ulrich Dobrindt, Institute of Hygiene, University of Münster, Münster, Germany 16.00 Coffee Protection by E. coli 83972, the US experience Barbara Trautner, Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA ABU protects against symptomatic recurrences, results of an RCT in adult females Tommaso Cai, Department of Urology, Santa Chiara Hospital, Trento, Italy Next generation tools for studying UPEC pathogenesis Swaine Chen, National University of Singapore and Genome Institute of Singapore WEDNESDAY August 27th 08.30 SESSION 5: NOVEL THERAPEUTIC APPROACHES Chairs: Robert Pickard, Chao Sing Ming Vaccine Candidates and Targets Harry Mobley, Department of Microbiology & Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA Antimicrobial peptides; Novel strategies to prevent UTI Annelie Brauner, Department of Microbiology, Tumor and Cell Biology, Division of Clinical Microbiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden Lactobacilli and probiotic Approaches to Therapy Ann Stapleton, Division of Allergy and Infectious Diseases & Clinical Research Center, Institute of Translational Health Sciences, University of Washington, Seattle, Washington, USA 10.30. Coffee Understanding urinary bladder mucosal immunity during UTI: opportunities for new therapeutic strategies Scott Hultgren, Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA Non-antibiotic prophylaxis for urinary tract infections Susanne Geerlings, Division Infectious Diseases, Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands D-Mannose – results of a randomized controlled trial Silvio Altarac, Department of Surgery and Urology, Zabok General Hospital, Zabok, Croatia Biomimickry of UPEC cytoinvasion: a novel concept for improved drug delivery in UTI Clara Maria Pichl, University of Vienna, Faculty of Life Sciences, Department of Pharmaceutical Tachnology and Biopharmaceutics, Wien, Austria 13.0014.00 Lunch 14.00 SESSION 6: ANTIBIOTIC RESISTANCE Chairs: Kurt Naber, Susanne Geerlings Molecular characterization of the multidrug resistant E. coli ST131 clone Mark Schembri, School of Chemistry and Molecular Biosciences, University of Queensland, St. Lucia, Queensland, Australia Perspectives on antibiotic resistance in UTI Javier Garau, Department of Medicine, Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain The role of surveillance in the control of resistance – the GPIU study as a model Florian Wagenlehner, Department of Urology, Pediatric Urology, and Andrology, Justus Liebig University, Giessen, Germany 16.00 Coffee FUTURE PERSPECTIVES An intergrated prospective study of childhood febrile UTI - future applications from bench to bedside Chao Sing Ming, Department of Pediatrics, KK Hospital, Singapore, Singapore UTI susceptibility markers, proteomics and risk assessment: A prospective study John Connolly, Singapore Immunology Network (SIgN), Biomedical Sciences Institutes, Agency for Science, Technology, and Research (A*STAR), Singapore, Singapore CONCLUDING REMARKS